Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 4, Open-label Trial Describing The Safety, Tolerability, And Immunogenicity Of The 13 Valent Pneumococcal Conjugate Vaccine In Preterm Compared To Term Infants

NCT01193335 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT01193335
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01193335 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 4, Open-label Trial Describing The Safety, Tolerability, And Immunogenicity Of The 13 Valent Pneumococcal Conjugate Vaccine In Preterm Compared To Term Infants
Lead sponsor
Pfizer
Phase
Phase 4
Overall status
Completed
Start date
October 31, 2010
Completion date
January 31, 2014
Enrollment
200 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

13-valent pneumococcal vaccine, immunization, premature birth, safety